Aclarion, Inc. has published a shareholder letter from CEO Brent Ness outlining the company's strategic progress and priorities for 2026, focusing on expanding adoption of its Nociscan platform that uses biomarkers and augmented intelligence algorithms to help physicians identify chronic low back pain sources. The commercial-stage healthcare technology company is pursuing reimbursement coverage from regional insurance providers in the United States as a critical step toward broader payer adoption, while also advancing initiatives in the United Kingdom.
The company's Nociscan platform represents a significant advancement in chronic pain management, leveraging Magnetic Resonance Spectroscopy data from MRI machines to extract and quantify chemical biomarkers associated with disc pain. Proprietary algorithms then analyze this biomarker data to indicate whether a disc may be a source of pain, providing physicians with critical insights to optimize treatment strategies. This technology addresses a substantial market need, as chronic low back pain affects millions globally and often presents diagnostic challenges for healthcare providers.
Key catalysts highlighted for 2026 include the initial readout from the ongoing CLARITY clinical trial expected in the fourth quarter, which will provide additional clinical evidence supporting Nociscan's efficacy. The company is also expanding commercial engagement with physicians and imaging centers while maintaining a strong balance sheet with cash runway extending into 2028, providing financial stability for continued execution of its strategic initiatives. For more information about the Nociscan platform, visit https://www.aclarion.com.
CEO Brent Ness emphasized that the company's 2026 focus remains on disciplined execution against key catalysts that can expand Nociscan adoption and strengthen the clinical and reimbursement foundation of the business. With increasing physician engagement, growing clinical evidence, and continued progress with payers, Aclarion believes it is well positioned to advance its mission of building a scalable technology platform for chronic low back pain. The full CEO Shareholder Letter is available on the company's website, and additional company news can be found at https://tinyurl.com/aconnewsroom.
The implications of Aclarion's progress extend beyond the company itself to the broader healthcare technology landscape. Successful reimbursement coverage could establish a precedent for AI-powered diagnostic tools in pain management, potentially accelerating adoption of similar technologies across medical specialties. For healthcare leaders and investors, Aclarion's approach demonstrates how AI integration with existing medical imaging infrastructure can create practical clinical solutions, while the company's financial position through 2028 provides stability for long-term development in a competitive market.
